Molecular Biology Automatic Analyzer Market Report 2026

The molecular biology automatic analyzer market size has grown strongly in recent years. It will grow from $2.56 billion in 2025 to $2.79 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to increasing adoption of automated lab equipment, growing demand for molecular diagnostics, rising investment in genomic research, expansion of biotechnology research centers, increasing prevalence of chronic and infectious diseases.

The molecular biology automatic analyzer market size is expected to see strong growth in the next few years. It will grow to $3.91 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to growing focus on personalized medicine, rising integration of ai and robotics in laboratories, increasing demand for high-throughput sequencing, expansion of molecular diagnostics in emerging markets, growing investment in cell and gene therapy development and Major trends in the forecast period include technology advancements in automation and ai, innovations in high-throughput molecular analysis, developments in multi-omics research, research and developments in gene editing technologies, technology advancements in sample preparation and assay accuracy.

The rising prevalence of infectious diseases is expected to drive the growth of the molecular biology automatic analyzer market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that invade the body, multiply, and cause symptoms and health complications. The increase in infectious diseases is fueled by factors like global travel, which accelerates the spread of pathogens across populations and borders. Molecular biology automatic analyzers support the diagnosis of infectious diseases by rapidly detecting and quantifying pathogens at the genetic level with high accuracy. They enhance patient outcomes by enabling early, precise, and efficient identification of infections, facilitating timely treatment. For example, in February 2024, according to the UK Health Security Agency, a UK-based government body, tuberculosis cases in England rose to 4,850 in 2023, marking a 10.7% increase from 4,380 cases in 2022. Therefore, the growing prevalence of infectious diseases is contributing to the expansion of the molecular biology automatic analyzer market.

Major companies operating in the molecular biology automatic analyzer market are concentrating on developing advanced diagnostic solutions, such as high-efficiency digital PCR platforms, to improve sensitivity, accuracy, and throughput in nucleic acid quantification for clinical and research applications. An efficient digital PCR platform is an automated system that partitions samples into thousands of microreactions, allowing precise, absolute quantification of target DNA or RNA sequences with minimal bias. This enables reliable detection of low-abundance biomarkers and enhances diagnostic confidence. For example, in September 2024, QIAGEN N.V., a Netherlands-based molecular diagnostics and life science tools company, introduced the QIAcuity Dx digital PCR system for clinical oncology testing. The platform combines digital PCR technology with an automated workflow, enabling laboratories to perform high-precision quantification of genetic targets relevant to cancer diagnostics and therapy monitoring. Its efficient digital PCR capabilities support robust data quality, simplified operation, and rapid turnaround times for clinical test results.

In May 2024, Bruker Corporation, an Italy-based provider of high-performance scientific instruments and analytical solutions, acquired ELITechGroup S.p.A. for approximately $1.02 billion (€870 million). Through this acquisition, Bruker expanded its molecular biology and in vitro diagnostics portfolio by integrating ELITech’s sample-to-answer molecular diagnostic systems and assays, strengthening its capabilities in infectious disease testing and biomedical solutions. ELITechGroup S.p.A. is a France-based in vitro diagnostics company specializing in molecular biology automatic analyzers and laboratory diagnostic solutions.

Major companies operating in the molecular biology automatic analyzer market are Thermo Fisher Scientific Inc., Becton Dickinson and Company, Siemens Healthineers AG, Agilent Technologies Inc., Illumina Inc., Hologic Inc., PerkinElmer Inc., bioMérieux SA, Sysmex Corporation, QIAGEN N.V., Bio-Rad Laboratories Inc., Roche Diagnostics, Hamilton Robotics, Tecan Group Ltd., Eppendorf SE, Takara Bio Inc., BGI Genomics Co. Ltd., Analytik Jena AG, Seegene Inc., Abbott Molecular Inc.

North America was the largest region in the molecular biology automatic analyzer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molecular biology automatic analyzer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the molecular biology automatic analyzer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs are impacting the molecular biology automatic analyzer market by increasing costs of imported optical components, microfluidic chips, electronic control units, and precision instrumentation. hospitals, research institutes, and diagnostic laboratories in north america and europe are most affected due to reliance on imported high-end analyzers, while asia-pacific faces export cost pressures. these tariffs can increase procurement costs and slow lab upgrades. however, they are encouraging local manufacturing, regional assembly, and development of cost-optimized automated molecular platforms.

A molecular biology automatic analyzer is an automated laboratory instrument developed to carry out molecular biology assays, including DNA or RNA extraction, amplification, sequencing, and protein analysis, with minimal human involvement. It enhances the efficiency, accuracy, and throughput of molecular experiments, reduces manual errors, and supports high-volume testing in research, diagnostic, and clinical settings.

The key product types of molecular biology automatic analyzers include real-time PCR systems, next-generation sequencing platforms, automated nucleic acid extractors, microarray analyzers, and integrated sample-to-answer systems. Real-time PCR systems automate amplification and quantification of nucleic acids for fast, accurate genetic detection. Technologies include optical detection, mass spectrometry, microfluidics, isothermal amplification, and digital PCR. Throughput ranges include high-, mid-, and low-throughput systems. Applications span genetic research, clinical diagnostics, infectious disease testing, oncology, precision medicine, pharmacogenomics, forensic and environmental testing, serving hospitals, labs, research institutes, pharma and biotech companies, CROs, and public health labs.

The molecular biology automatic analyzer market consists of DNA/RNA extraction, PCR amplification, real-time PCR, sequencing analysis, genotyping, protein expression analysis, microarray analysis, gene synthesis services, cell-based assays, and bioinformatics data analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The molecular biology automatic analyzer market includes sales of automated PCR machines, real-time PCR systems, DNA sequencers, RNA sequencers, microarray scanners, nucleic acid extractors, automated liquid handlers, gene synthesizers, protein analyzers, and lab automation robots. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.